Navigation Links
Actos Bladder Cancer Lawsuits Move Forward, with Issuance of New Order in Federal Actos Litigation, Bernstein Liebhard LLP Reports

New York, New York (PRWEB) September 08, 2013

Actos lawsuits( filed on behalf of people who allegedly developed bladder cancer due to prolonged use of the Type 2 diabetes drug continue to move forward in a multidistrict litigation underway in U.S. District Court, Western District of Louisiana, Bernstein Liebhard LLP reports. According to an Order issued by the Court on August 26th, the parties have been directed to meet and confer, in person, prior to the filing of certain motions, in order to attempt to resolve issues before they are brought to the attention of the Court. (In re: Actos Product Liability Litigation, MDL No. 2299)

“More than than two years after U.S. regulators warned of the potential for Actos bladder cancer, our Firm continues to hear from long-term users of this drug who developed the disease. We are pleased to see federal Actos lawsuits moving forward,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free lawsuit evaluations to long-term Actos users who were diagnosed with bladder cancer, allegedly due to their use of the Type 2 diabetes drug.

Actos Bladder Cancer
The litigation surrounding Actos has been growing since June 2011, when the U.S. Food & Drug Administration (FDA) warned that use of Actos for one year or more had been linked to the development of bladder cancer. Court documents indicate that more than 2,500 Actos lawsuits have been filed in the federal multidistrict litigation underway in Louisiana. All of the claims pending in the proceeding allege that long-term users of Actos are at a higher risk for bladder cancer, and accuse Takeda Pharmaceuticals and other defendants of concealing their knowledge of that risk and failing to provide adequate warnings to the public and medical community. The federal litigation’s first bellwether trial will begin on January 27, 2014, while its second Actos bladder cancer trial will commence on April 14, 2014.

While Actos lawsuits have yet to go trial in the federal litigation, some cases have gone before a jury in state proceedings. According to court documents, the nation’s second Actos bladder cancer trial is now underway in Maryland state court. During opening arguments earlier this week, an attorney for the Plaintiff claimed that Takeda knew as early as 2005 that research had linked prolonged Actos use to bladder cancer, but waited six years to issue a public warning. The attorney further asserted that this delay allowed Takeda to increase sales of Actos. (An v. Nieberlein, 24-C12003565, Circuit Court for the City of Baltimore, State of Maryland.)

The nation’s first state trial involving Actos bladder cancer allegations ended in April, with a California Superior court jury awarding more than $6 million to the Plaintiff. However, the judge overseeing the case granted Takeda Pharmaceuticals’ request to set aside the verdict. (Cooper v. Takeda Pharmaceuticals America Inc., CGC-12-518535, California Superior Court)

Patients who took Actos for more than a year and were diagnosed with bladder cancer may be entitled to compensation for medical expenses, lost wages, pain and suffering, and more. Learn More about filing an Actos bladder cancer lawsuit by visiting Bernstein Liebhard LLP’s website. For additional information, please contact Bernstein Liebhard LLP today by calling 800-511-5092.

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Lawsuit Alleges Takeda Pharmaceutical Co., Maker of Diabetes Drug Actos, Didn’t Warn of the Drug’s Risks Soon Enough; Parker Waichman LLP Responds
2. Actos Lawsuit News: Bernstein Liebhard LLP Notes Start of Second Actos Bladder Cancer Trial in Maryland State Court
3. Actos Bladder Cancer Lawsuits Help: Resource4thePeople Reports Number of Consolidated Federal Cases Climbs to over 2,500
4. Actos Lawsuits Move Forward Following Latest Status Conference in Federal Actos Bladder Cancer Litigation
5. Oregon Man Developed Bladder Cancer Brought on by Years of Ingesting Diabetes Drug Actos, Alleges Lawsuit Filed by Parker Waichman LLP
6. Florida Woman Developed Bladder Cancer After Taking Actos to Treat her Type II Diabetes, Alleges Lawsuit Filed by Parker Waichman LLP
7. Years of Ingesting Diabetes Drug Actos Caused Florida Man to Develop Bladder Cancer, Alleges Lawsuit Filed by Parker Waichman LLP
8. Actos Lawsuits Alleging Bladder Cancer Update: Resource4thePeople Reports Judge Continues to Move Multidistrict Litigation Forward
9. Organic Valley Presents Lactose Free Whole Milk and Lactose Free Half & Half
10. Actos Lawsuit – Status Conference Convened in Federal Actos Bladder Cancer Multidistrict Litigation, Bernstein Liebhard LLP Reports
11. Actos Lawsuit News: More Than a Dozen Lawsuits Filed in West Virginia, Rottenstein Law Group LLP Reports
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... Insightra Medical, Inc. and Novus ... technology for soft tissue repair in the US via Insightra’s national direct sales ... mesh intended to support and reinforce soft tissue for 6-9 months before absorbing ...
(Date:11/30/2015)... ... 30, 2015 , ... SIMmersion’s ability to present dynamic scenarios ... of the future. To reach an audience of key visionaries and reformers in ... Chicago, organized by the American Medical Association. , AMA President Steven Stack, ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... enterprise Time and Attendance/Workforce Management cloud-based solutions, announced today that it has ... competencies in the Application Development, demonstrating a “best-in-class” ability and commitment to ...
(Date:11/30/2015)... November 30, 2015 (PRWEB) , ... ... ... and Winscribe are pleased to announce their strategic partnership at the Radiological ... consultants, SpeechCheck, Inc., and Winscribe, global providers of cutting-edge dictation and speech-enabled ...
(Date:11/30/2015)... ... 30, 2015 , ... World Patent Marketing , a ... household invention that provides an economical and easy way of gaining customized curtains. ... at 2.6%," says Scott Cooper, CEO and Creative Director of World Patent Marketing. ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , November 26, 2015 /PRNewswire/ ... --> adds "Global ... and "Investigation Report on China Repaglinide ... 2021 forecasts data and information to ... . --> ...
(Date:11/26/2015)... , Nov. 26, 2015 Research and ... of the "2016 Future Horizons and Growth ... Market: Supplier Shares, Country Segment Forecasts, Competitive Intelligence, ... --> --> ... of the Italian therapeutic drug monitoring market, including ...
(Date:11/26/2015)... November 26, 2015 ... addition of the  "2016 Future Horizons ... Cell Surface Marker Testing Market: Supplier ... to their offering.  --> ... of the  "2016 Future Horizons and ...
Breaking Medicine Technology: